Today Johnson & Johnson announced a collaboration between Johnson & Johnson Services, Inc. and a subsidiary of HP Inc. The partnership will be focused on using 3D printing technologies to create better healthcare outcomes at a reduced cost. By working together, the companies plan to combine their scientific, clinical, material science and technological expertise to
Johnson & Johnson have announced positive results for the first quarter of 2015, beating earnings expectations. However, the company has been forced to lower their full-year expectations for 2015 from $6.12-$6.27 per share to $6.04-$6.19, as a result of exchange rates with a strong US dollar. The negative currency effect is expected to continue to
Johnson & Johnson have reported strong results for their second quarter of 2013, with an 8.5% increase in sales. The increase was aided by robust results from their prostate cancer drug, Zytiga. Net income reached $3.83 billion, a major increase from the $1.41 billion from the previous year’s quarter 2 period, aided by the gain
Cancer Research Technology (CRT) and the Institute of Cancer Research (ICR) announced earlier today that they have partnered with Johnson & Johnson unit, Janssen Biotech, in an agreement to discover a potential new drug for the blood cancer, multiple myeloma. The partnership is aiming to identify molecules and develop them into experimental therapies that block
Johnson & Johnson have announced an 8% rise in sales for their fourth quarter, aided by strong results from their pharmaceutical division. The group net income for the quarter was $2.57 billion, in comparison to $218 million in the fourth quarter of the previous year, when net income was affected by charges of $2.86 billion.
Johnson & Johnson (J&J) yesterday reported a 12.5% growth in earnings for their first quarter, assisted by sales of new products, the most noticeable being the prostate cancer drug Zytiga. The group’s net earnings came in at $3.91 billion, while turnover fell 0.2% to $16.14 billion. Worldwide pharmaceutical sales were up 1.2% to $6.13 billion,
Johnson & Johnson have entered into an agreement to help develop a cancer compound discovered by Pharmacyclics in a deal that could be worth close to $1 billion to Pharmacyclics. Johnson & Johnson’s Janssen Biotech subsidiary will work together to develop and market the drug, known as PCI-32765, which is currently involved in a range
